Abstract
Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.
Keywords: Bevacizumab, cilengitide, glioblastoma, resistance, temozolomide, toxicity, VEGF, basement membrane, extracellular matrix, hepatocyte growth factor/scatter factor, hypoxia inducible factor-1a, overall survival, phosphatase and tensin homolog, vascular endotelial growth factor, progression free surivival
Current Cancer Drug Targets
Title: Anti-Angiogenic Approaches to Malignant Gliomas
Volume: 12 Issue: 3
Author(s): R. Soffietti, E. Trevisan, L. Bertero, C. Bosa and R. Ruda
Affiliation:
Keywords: Bevacizumab, cilengitide, glioblastoma, resistance, temozolomide, toxicity, VEGF, basement membrane, extracellular matrix, hepatocyte growth factor/scatter factor, hypoxia inducible factor-1a, overall survival, phosphatase and tensin homolog, vascular endotelial growth factor, progression free surivival
Abstract: Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing. Other promising antiangiogenic compounds are cilengitide and continuous temozolomide. Toxicity is acceptable. Open issues are represented by patterns of tumor progression, resistance mechanisms and biomarkers.
Export Options
About this article
Cite this article as:
Soffietti R., Trevisan E., Bertero L., Bosa C. and Ruda R., Anti-Angiogenic Approaches to Malignant Gliomas, Current Cancer Drug Targets 2012; 12 (3) . https://dx.doi.org/10.2174/156800912799277584
DOI https://dx.doi.org/10.2174/156800912799277584 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Targeting EGFR and HER2 with 211At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells
Current Radiopharmaceuticals From Axonal Transport to Mitochondrial Trafficking: What Can We Learn from Manganese-Enhanced MRI Studies in Mouse Models of Alzheimers Disease?
Current Medical Imaging The Immunoregulatory Protein Human B7H3 is a Tumor-Associated Antigen that Regulates Tumor Cell Migration and Invasion
Current Cancer Drug Targets MDM4 (MDMX) and its Transcript Variants
Current Genomics Gene Expression Analysis Approach to Establish Possible Links Between Parkinson's Disease, Cancer and Cardiovascular Diseases
CNS & Neurological Disorders - Drug Targets Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect
Current Medicinal Chemistry Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents Adenovirus Vector Production and Purification
Current Gene Therapy Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Human Microdialysis
Current Pharmaceutical Biotechnology Autophagy: A Major Target of Cadmium Nephrotoxicity
Current Chemical Biology Subject Index To Volume 6
Central Nervous System Agents in Medicinal Chemistry